• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

    11/14/24 9:21:21 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SKYE alert in real time by email
    SC 13G/A 1 sb-sc13ga_093024.htm AMENDMENT TO FORM SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Skye Bioscience, Inc.

    (Name of Issuer)

     
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

     

    83086J200

    (CUSIP Number)

     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 2 of 9

     

    CUSIP No.    83086J200    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,315,146 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,315,146 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,315,146 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.3%(1)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

     

    (1)Based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 3 of 9

     

    CUSIP No. 83086J200    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,315,146 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,315,146 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,315,146 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.3%(1)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    (1)Based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 4 of 9

     

    CUSIP No. 83086J200    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,315,146 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,315,146 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,315,146 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.3%(1)

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

     
    (1)Based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 5 of 9

     

    CUSIP No. 83086J200    

     

    Item 1(a).   Name of Issuer: Skye Biosciences, Inc. (the “Issuer”)
         
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:   

    11250 El Camino Real, Suite 100
    San Diego, California 92130

         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.001 per share (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 83086J200
         
    Item 3.   If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

    Page 6 of 9

     

    CUSIP No. 83086J200    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

      

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 30,338,290 shares of Common Stock outstanding as of November 6, 2024, as set forth in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    Page 7 of 9

     

    CUSIP No. 83086J200    

      

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: November 14, 2024  
         
     

    Altium Capital Management, LP 

     

     
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
         
      By: Altium Growth GP, LLC  
      Its: General Partner  
           
      Signature:   /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC  
       
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     

     

      

    Page 8 of 9

     

    EXHIBIT INDEX 

     

    EXHIBIT 1:Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

     

    Get the next $SKYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SKYE

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    9/30/2024$20.00Sector Outperform
    Scotiabank
    9/10/2024$15.00Mkt Outperform
    JMP Securities
    7/9/2024$18.00Buy
    Craig Hallum
    5/23/2024$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SKYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Twitty Christopher claimed ownership of 81,242 shares (SEC Form 3)

      3 - Skye Bioscience, Inc. (0001516551) (Issuer)

      4/25/25 4:03:41 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Chief Financial Officer Arsenault Kaitlyn sold $215,754 worth of shares (43,216 units at $4.99), decreasing direct ownership by 21% to 167,522 units (SEC Form 4)

      4/A - Skye Bioscience, Inc. (0001516551) (Issuer)

      2/28/25 6:54:45 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schwab Andrew J.

      4 - Skye Bioscience, Inc. (0001516551) (Issuer)

      2/26/25 7:45:56 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Leadership Updates

    Live Leadership Updates

    See more
    • Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

      SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli

      9/3/24 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

      SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi

      8/9/24 5:59:37 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

      SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company's operational and clinical expertise. Our strategic focus on the Nimacimab metabolic program will be supported by an evolving board as Keith Ward, PhD, and Praveen Tyle, PhD, resign from their roles as Boa

      7/3/24 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    SEC Filings

    See more
    • Skye Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Skye Bioscience, Inc. (0001516551) (Filer)

      5/8/25 4:05:16 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Skye Bioscience Inc.

      10-Q - Skye Bioscience, Inc. (0001516551) (Filer)

      5/8/25 4:03:41 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Skye Bioscience Inc.

      DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)

      4/25/25 4:01:21 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

      SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation development collaboration with Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives. The partnership aims to develop a higher concentration formulation of Skye's CB1 inhibitor, nimacimab, using Arecor's proprietary formulation technology platform, Arestat™. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase 2a CBeyond™ clinical

      5/19/25 5:00:49 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the "2024 Inducement Plan"). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively

      5/13/25 4:05:00 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

      • This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic he

      5/13/25 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Skye Bioscience

      William Blair initiated coverage of Skye Bioscience with a rating of Outperform

      2/28/25 7:31:27 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Skye Bioscience with a new price target

      Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00

      9/30/24 7:51:18 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Skye Bioscience with a new price target

      JMP Securities initiated coverage of Skye Bioscience with a rating of Mkt Outperform and set a new price target of $15.00

      9/10/24 7:59:52 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

      SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)

      11/14/24 10:02:54 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

      SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)

      11/14/24 9:21:21 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Skye Bioscience Inc.

      SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)

      8/14/24 4:59:17 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Financials

    Live finance-specific insights

    See more
    • Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

      Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage b

      5/8/25 4:01:00 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the c

      5/7/25 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removedPhase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy dataCash runway projected through at least Q1 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial resu

      3/20/25 4:01:00 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care